Assessment of Thrombin Generation: Useful or Hype?

 

 Buy Article Permissions and Reprints

ABSTRACT

Thrombin plays an important role in hemostasis through its multiple functions across blood coagulation, platelet activation, and fibrinolysis. The measurement of thrombin generation is therefore viewed as a potentially useful test that could be applied to the screening, monitoring, and/or diagnosis of hemostatic abnormalities. Indeed, advances in thrombin generation assays have created significant interest and debate as to whether they may provide a more physiologically relevant testing system than do traditional coagulation tests. A variety of thrombin generation assays, including commercially available systems, have been investigated for their correlation with hypocoagulable and hypercoagulable states. Although there is an extensive body of literature that has investigated the application of thrombin generation assays, some limitations remain. These include poor standardization of reagents and methods and a lack of large prospective studies that demonstrate clear relationships between thrombin generation with bleeding and thrombosis phenotypes, as well as with monitoring anticoagulation. Whether thrombin generation assays become more “useful” than “hype” will require well-designed, large, prospective multicenter trials using standardized methods.

REFERENCES

• 1 Hemker H C, Beguin S. Thrombin generation in plasma: its assessment via the endogenous thrombin potential.  Thromb Haemost. 1995;  74 134-138
  PubMedGoogle Scholar
• 2 Lippi G, Favaloro E J. Activated partial thromboplastin time: new tricks for an old dogma.  Semin Thromb Hemost. 2008;  34 604-611
  Article in Thieme ConnectPubMedGoogle Scholar
• 3 Davie E W, Ratnoff O D. Waterfall sequence for intrinsic blood clotting.  Science. 1964;  145 1310-1312
  CrossrefPubMedGoogle Scholar
• 4 Macfarlane R G. An enzyme cascade in the blood clotting mechanism, and its function as a a biochemical amplifier.  Nature. 1964;  202 498-499
  CrossrefPubMedGoogle Scholar
• 5 Osterud B, Rapaport S I. Activation of factor IX by the reaction product of tissue factor and factor VII: additional pathway for initiating blood coagulation.  Proc Natl Acad Sci U S A. 1977;  74 5260-5264
  CrossrefPubMedGoogle Scholar
• 6 Sanders N L, Bajaj S P, Zivelin A, Rapaport S I. Inhibition of tissue factor/factor VIIa activity in plasma requires factor X and an additional plasma component.  Blood. 1985;  66 204-212
  PubMedGoogle Scholar
• 7 Gailani D, Broze Jr G J. Factor XI activation in a revised model of blood coagulation.  Science. 1991;  253 909-912
  CrossrefPubMedGoogle Scholar
• 8 Hoffman M, Monroe III D M. A cell-based model of hemostasis.  Thromb Haemost. 2001;  85 958-965
  PubMedGoogle Scholar
• 9 McVey J H. Tissue factor pathway.  Best Pract Res Clin Haematol. 1999;  12 361-372
  CrossrefPubMedGoogle Scholar
• 10 Crawley J T, Zanardelli S, Chion C K, Lane D A. The central role of thrombin in hemostasis.  J Thromb Haemost. 2007;  5(Suppl 1) 95-101
  CrossrefPubMedGoogle Scholar
• 11 Righini M, Perrier A, De Moerloose P, Bounameaux H. D-dimer for venous thromboembolism diagnosis: 20 years later.  J Thromb Haemost. 2008;  6 1059-1071
  CrossrefPubMedGoogle Scholar
• 12 Stegnar M, Vene N, Bozic M. Do haemostasis activation markers that predict cardiovascular disease exist?.  Pathophysiol Haemost Thromb. 2003;  33 302-308
  CrossrefPubMedGoogle Scholar
• 13 Macfarlane R G, Biggs R. A thrombin generation test; the application in haemophilia and thrombocytopenia.  J Clin Pathol. 1953;  6 3-8
  CrossrefPubMedGoogle Scholar
• 14 Pitney W R, Dacie J V. A simple method of studying the generation of thrombin in recalcified plasma; application in the investigation of haemophilia.  J Clin Pathol. 1953;  6 9-14
  CrossrefPubMedGoogle Scholar
• 15 Baglin T. The measurement and application of thrombin generation.  Br J Haematol. 2005;  130 653-661
  CrossrefPubMedGoogle Scholar
• 16 Hemker H C, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential.  Thromb Haemost. 1993;  70 617-624
  PubMedGoogle Scholar
• 17 Hemker H C, Willems G M, Beguin S. A computer assisted method to obtain the prothrombin activation velocity in whole plasma independent of thrombin decay processes.  Thromb Haemost. 1986;  56 9-17
  PubMedGoogle Scholar
• 18 Tappenden K A, Gallimore M J, Evans G, Mackie I J, Jones D W. Thrombin generation: a comparison of assays using platelet-poor and -rich plasma and whole blood samples from healthy controls and patients with a history of venous thromboembolism.  Br J Haematol. 2007;  139 106-112
  CrossrefPubMedGoogle Scholar
• 19 Stief T W. Influence of the surface on thrombin generation.  Int J Lab Hematol. 2008;  30 269-277
  CrossrefPubMedGoogle Scholar
• 20 Hemker H C, Al Dieri R, De Smedt E, Beguin S. Thrombin generation, a function test of the haemostatic-thrombotic system.  Thromb Haemost. 2006;  96 553-561
  Article in Thieme ConnectPubMedGoogle Scholar
• 21 van Veen J J, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet?.  Br J Haematol. 2008;  142 889-903
  CrossrefPubMedGoogle Scholar
• 22 Berntop E, Salvagno G L. Standardization and clinical utility of thrombin generation assays.  Semin Thromb Hemost. 2008;  34 670-682
  Article in Thieme ConnectPubMedGoogle Scholar
• 23 Dargaud Y, Beguin S, Lienhart A et al.. Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and B.  Thromb Haemost. 2005;  93 475-480
  PubMedGoogle Scholar
• 24 Varadi K, Turecek P L, Schwarz H P. Thrombin generation assay and other universal tests for monitoring haemophilia therapy.  Haemophilia. 2004;  10(Suppl 2) 17-21
  PubMedGoogle Scholar
• 25 Beltran-Miranda C P, Khan A, Jaloma-Cruz A R, Laffan M A. Thrombin generation and phenotypic correlation in haemophilia A.  Haemophilia. 2005;  11 326-334
  CrossrefPubMedGoogle Scholar
• 26 Turecek P L, Varadi K, Keil B et al.. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay.  Pathophysiol Haemost Thromb. 2003;  33 16-22
  CrossrefPubMedGoogle Scholar
• 27 Rugeri L, Beguin S, Hemker C et al.. Thrombin-generating capacity in patients with von Willebrand's disease.  Haematologica. 2007;  92 1639-1646
  CrossrefPubMedGoogle Scholar
• 28 Beguin S, Keularts I, Al Dieri R et al.. Fibrin polymerization is crucial for thrombin generation in platelet-rich plasma in a VWF-GPIb-dependent process, defective in Bernard-Soulier syndrome.  J Thromb Haemost. 2004;  2 170-176
  CrossrefPubMedGoogle Scholar
• 29 Beguin S, Kumar R, Keularts I et al.. Fibrin-dependent platelet procoagulant activity requires GPIb receptors and von Willebrand factor.  Blood. 1999;  93 564-570
  PubMedGoogle Scholar
• 30 Reverter J C, Beguin S, Kessels H et al.. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis”.  J Clin Invest. 1996;  98 863-874
  CrossrefPubMedGoogle Scholar
• 31 Al Dieri R, Peyvandi F, Santagostino E et al.. The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding.  Thromb Haemost. 2002;  88 576-582
  PubMedGoogle Scholar
• 32 al Dieri R, Alban S, Beguin S, Hemker H C. Thrombin generation for the control of heparin treatment, comparison with the activated partial thromboplastin time.  J Thromb Haemost. 2004;  2 1395-1401
  CrossrefPubMedGoogle Scholar
• 33 Al Dieri R, Alban S, Beguin S, Hemker H C. Fixed dosage of low-molecular-weight heparins causes large individual variation in coagulability, only partly correlated to body weight.  J Thromb Haemost. 2006;  4 83-89
  PubMedGoogle Scholar
• 34 Gerotziafas G T, Elalamy I, Depasse F, Perzborn E, Samama M M. In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.  J Thromb Haemost. 2007;  5 886-888
  CrossrefPubMedGoogle Scholar
• 35 Gerotziafas G T, Depasse F, Chakroun T et al.. Comparison of the effect of fondaparinux and enoxaparin on thrombin generation during in-vitro clotting of whole blood and platelet-rich plasma.  Blood Coagul Fibrinolysis. 2004;  15 149-156
  CrossrefPubMedGoogle Scholar
• 36 Beilfu ACommentStCommentEndCommentBody, Grandoch M, Wenzel F et al.. Differential effects of factor IIa inhibitors on the endogenous thrombin potential.  Ther Drug Monit. 2008;  , September 26 (Epub ahead of print)
  PubMedGoogle Scholar
• 37 Wegert W, Graff J, Kaiser D et al.. Effects of antiplatelet agents on platelet-induced thrombin generation.  Int J Clin Pharmacol Ther. 2002;  40 135-141
  PubMedGoogle Scholar
• 38 Ignjatovic V, Summerhayes R, Yip Y Y, Monagle P. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults.  Thromb Res. 2008;  122 709-714
  CrossrefPubMedGoogle Scholar
• 39 Gatt A, van Veen J J, Woolley A M et al.. Thrombin generation assays are superior to traditional tests in assessing anticoagulation reversal in vitro.  Thromb Haemost. 2008;  100 350-355
  PubMedGoogle Scholar
• 40 Brodin E, Seljeflot I, Arnesen H et al.. Endogenous thrombin potential (ETP) in plasma from patients with AMI during antithrombotic treatment.  Thromb Res. 2009;  123 573-579
  CrossrefPubMedGoogle Scholar
• 41 Gatt A, van Veen J J, Bowyer A et al.. Wide variation in thrombin generation in patients with atrial fibrillation and therapeutic international normalized ratio is not due to inflammation.  Br J Haematol. 2008;  142 946-952
  CrossrefPubMedGoogle Scholar
• 42 Curvers J, Thomassen M C, Rimmer J et al.. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.  Thromb Haemost. 2002;  88 5-11
  PubMedGoogle Scholar
• 43 Duchemin J, Pittet J L, Tartary M et al.. A new assay based on thrombin generation inhibition to detect both protein C and protein S deficiencies in plasma.  Thromb Haemost. 1994;  71 331-338
  PubMedGoogle Scholar
• 44 Gardiner C, Machin S J, Mackie I J. Measuring thrombin generation based sensitivity to activated protein C using an automated coagulometer (ACL 9000).  Int J Lab Hematol. 2008;  30 261-268
  CrossrefPubMedGoogle Scholar
• 45 Tchaikovski S N, van Vliet H A, Thomassen M C et al.. Effect of oral contraceptives on thrombin generation measured via calibrated automated thrombography.  Thromb Haemost. 2007;  98 1350-1356
  PubMedGoogle Scholar
• 46 Regnault V, Beguin S, Lecompte T. Calibrated automated thrombin generation in frozen-thawed platelet-rich plasma to detect hypercoagulability.  Pathophysiol Haemost Thromb. 2003;  33 23-29
  CrossrefPubMedGoogle Scholar
• 47 Rosenkranz A, Hiden M, Leschnik B et al.. Calibrated automated thrombin generation in normal uncomplicated pregnancy.  Thromb Haemost. 2008;  99 331-337
  Article in Thieme ConnectPubMedGoogle Scholar
• 48 Regnault V, Beguin S, Wahl D et al.. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants.  Thromb Haemost. 2003;  89 208-212
  PubMedGoogle Scholar
• 49 Lecompte T, Wahl D, Perret-Guillaume C et al.. Hypercoagulability resulting from opposite effects of lupus anticoagulants is associated strongly with thrombotic risk.  Haematologica. 2007;  92 714-715
  CrossrefPubMedGoogle Scholar
• 50 Eichinger S, Hron G, Kollars M, Kyrle P A. Prediction of recurrent venous thromboembolism by endogenous thrombin potential and D-dimer.  Clin Chem. 2008;  54 2042-2048
  CrossrefPubMedGoogle Scholar
• 51 Besser M, Baglin C, Luddington R, van Hylckama Vlieg A, Baglin T. High rate of unprovoked recurrent venous thrombosis is associated with high thrombin-generating potential in a prospective cohort study.  J Thromb Haemost. 2008;  6 1720-1725
  CrossrefPubMedGoogle Scholar
• 52 van Hylckama Vlieg A, Christiansen S C, Luddington R et al.. Elevated endogenous thrombin potential is associated with an increased risk of a first deep venous thrombosis but not with the risk of recurrence.  Br J Haematol. 2007;  138 769-774
  CrossrefPubMedGoogle Scholar

Murray AdamsPh.D. M.A.I.M.S. 

School of Human Life Sciences, University of Tasmania

Tasmania 7250, Australia

Email: Murray.Adams@utas.edu.au